ChitoLytic Competitors

Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.

At Proventus Bioscience, we turn microbial science into real-world impact. We’re a Canadian CDMO (Contract Development and Manufacturing Organization) specialized in microbial biosolutions. Whether you're a startup, innovator, or industrial player, we help you scale biology, from idea to implementation. What we do: • Strain selection, optimization & R&D • Pilot-scale testing & custom formulation • Industrial fermentation (liquid & solid) • White-label & OEM-ready product delivery Our solutions are designed for sectors where biology beats chemistry: agriculture, food & nutrition, wastewater, circular materials, and more. From early-stage biotech to global industry leaders, we deliver precision, performance, and purpose. Let’s bring your biological innovation to life. Based in Canada. Trusted globally.

Medical device/biopharmaceutical startup developing medicated stickers capable of delivering antihistamines and other small molecules to children. Target markets: Children, elderly, bariatric patients, dysphagia sufferers Part of the Velocity Incubator, Communitech network, and Bayer Grants4Apps accelerator